Darmiyan
Darmiyan is a YC Summer 2017 (S17) company. Based in San Francisco, CA, USA. Team of 8.
About Darmiyan
Summary
Darmiyan builds FDA-cleared medical AI software, BrainSee, that analyzes standard MRI scans to detect early signs of Alzheimer's disease and other neurodegenerative conditions. Its quantitative virtual microscopy reads changes in brain tissue architecture that conventional MRI interpretation misses, giving neurologists and healthcare providers a non-invasive window into disease progression before symptoms become severe. The software replaces the need for invasive or costly diagnostic procedures currently used to assess neurodegeneration at early stages.
Go-to-market
Darmiyan targets patients, healthcare providers, and pharmaceutical companies, offering BrainSee as a brain health screening and monitoring tool that integrates into existing imaging workflows.
From the Y Combinator listing
Early detection of Alzheimer's disease
Novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.
Facts
- Healthcare / Healthcare -> Diagnostics
- San Francisco, CA, USA
- 8
- Active
- Early
Founders (2)
- Kaveh Vejdani
- Padideh Kamali-Zare
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works